Merck & Co. (MRK: 35.61 ,0.00 ,0.00%) has withdrawn its application for European regulatory approval of an asthma treatment, citing outstanding questions by regulators.
The Merck product was approved in June by the U.S. Food and Drug Administration under the brand name Dulera. It is a fixed-dose combination of two older asthma drugs, mometasone furoate and formoterol fumarate dihydrate, which are sold individually under the brands Nasonex and Foradil.
via foxbusiness.com
No comments:
Post a Comment